BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2015;56:1252-1260. [PMID: 25120049 DOI: 10.3109/10428194.2014.953145] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, Uldrick TS, Yarchoan R, Medeiros LJ, Li Y, Fajgenbaum DC, Young KH. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017;129:1658-1668. [PMID: 28100459 DOI: 10.1182/blood-2016-11-748855] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 18.3] [Reference Citation Analysis]
2 Fajgenbaum DC. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Hematology Am Soc Hematol Educ Program 2018;2018:318-25. [PMID: 30504327 DOI: 10.1182/asheducation-2018.1.318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Paydas S. Tafro syndrome: Critical review for clinicians and pathologists. Crit Rev Oncol Hematol 2018;128:88-95. [PMID: 29958635 DOI: 10.1016/j.critrevonc.2018.05.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
4 Han EJ, O JH, Jung SE, Park G, Choi BO, Jeon YW, Min GJ, Cho SG. FDG PET/CT Findings of Castleman Disease Assessed by Histologic Subtypes and Compared with Laboratory Findings. Diagnostics (Basel) 2020;10:E998. [PMID: 33255420 DOI: 10.3390/diagnostics10120998] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Pan Y, Cui Z, Wang S, Zheng D, Deng Z, Tian X, Guo H, Bao W, Zhou S, Wang Y. Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature. BMC Nephrol 2020;21:528. [PMID: 33276741 DOI: 10.1186/s12882-020-02191-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016;3:e163-e175. [PMID: 27063975 DOI: 10.1016/s2352-3026(16)00006-5] [Cited by in Crossref: 119] [Cited by in F6Publishing: 68] [Article Influence: 23.8] [Reference Citation Analysis]
7 Ferrario A, Merli M, Basilico C, Maffioli M, Passamonti F. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma. Expert Opin Investig Drugs 2017;26:367-73. [PMID: 28140696 DOI: 10.1080/13543784.2017.1288213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Foster CH, Elahi C, Cheney S, Trier T, Torabi A, Manglik N. Thoracic Paraspinal Castleman Disease in a Young Mexican-American Man with Postcoital Hematuria. World Neurosurg 2018;120:36-42. [PMID: 30165219 DOI: 10.1016/j.wneu.2018.08.091] [Reference Citation Analysis]
9 Dong Y, Liu B, Ju G, Cai J, Zhang N, Wang LH. Concomitant perinephric Castleman disease and renal cell carcinoma initially suspected to be metastasis: A case report and 24 months follow up. Urol Case Rep 2019;22:70-2. [PMID: 30479965 DOI: 10.1016/j.eucr.2018.08.019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Liu HL, Fan L, Li JY. [Progress in the diagnosis and treatment of Castleman disease]. Zhonghua Xue Ye Xue Za Zhi 2020;41:697-700. [PMID: 32942829 DOI: 10.3760/cma.j.issn.0253-2727.2020.08.017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Gunda D, Naughton J, Stevens SG, Perini MV. Castleman's disease masquerading as pancreatic neuroendocrine tumour. BMJ Case Rep 2021;14:e242597. [PMID: 34167983 DOI: 10.1136/bcr-2021-242597] [Reference Citation Analysis]
12 Fajgenbaum DC. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood 2018;132:2323-30. [PMID: 30487129 DOI: 10.1182/blood-2018-05-848671] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
13 Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129:1646-1657. [PMID: 28087540 DOI: 10.1182/blood-2016-10-746933] [Cited by in Crossref: 171] [Cited by in F6Publishing: 149] [Article Influence: 42.8] [Reference Citation Analysis]
14 Liu S, Wang Y, Hu T, Zhang C, Zheng Z. Peripheral T cell lymphoma coexisting with Castleman's disease: A case report and literature review. Medicine (Baltimore) 2020;99:e18650. [PMID: 31914048 DOI: 10.1097/MD.0000000000018650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yang D, Zhou X, Zhao Y, Cao S, Su A, Zhang X, Xu Y, Zhang X. A rare case of multicentric castleman's disease transforms into multiple myeloma and its successful treatment. Cancer Biol Ther 2018;19:949-52. [PMID: 29580142 DOI: 10.1080/15384047.2018.1456606] [Reference Citation Analysis]
16 van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Chadburn A, Fajgenbaum DC. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv 2020;4:6039-50. [PMID: 33284946 DOI: 10.1182/bloodadvances.2020003334] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
17 Chung SJ, Ahn KM, Oh JH, Shim JS, Park HW. Incidence rates of severe cutaneous adverse reactions due to antiseizure medication: A nationwide study using health claims data in Korea. Epilepsia 2021;62:250-7. [PMID: 33188522 DOI: 10.1111/epi.16751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Choi DL, Brannock K, Tang AL. Castleman Disease Presenting as a Parapharyngeal Mass: A Case Report and Review of the Literature. Clin Med Insights Case Rep 2019;12:1179547619853799. [PMID: 31258339 DOI: 10.1177/1179547619853799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Johnson DA, Lieberman D, Inadomi JM, Ladabaum U, Becker RC, Gross SA, Hood KL, Kushins S, Pochapin M, Robertson DJ. Increased Post-procedural Non-gastrointestinal Adverse Events After Outpatient Colonoscopy in High-risk Patients. Clinical Gastroenterology and Hepatology 2017;15:883-891.e9. [DOI: 10.1016/j.cgh.2016.12.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Bracale U, Pacelli F, Milone M, Bracale UM, Sodo M, Merola G, Troiani T, Di Salvo E. Laparoscopic treatment of abdominal unicentric castleman's disease: a case report and literature review. BMC Surg 2017;17:38. [PMID: 28403848 DOI: 10.1186/s12893-017-0238-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
21 Kaga H, Kurahashi H, Kubota A, Hatano Y, Nanjo H, Wakui H, Takahashi N. Successful rituximab treatment of an elderly Japanese patient with HHV8-positive, HIV-negative multicentric Castleman disease. Int J Hematol 2021. [PMID: 34591291 DOI: 10.1007/s12185-021-03222-7] [Reference Citation Analysis]
22 Singh R, Prasher R, Mohan S, Thakur B. Retroperitoneal unicentric Castleman's disease-A case report and review of literature. Int J Surg Case Rep 2021;86:106325. [PMID: 34425426 DOI: 10.1016/j.ijscr.2021.106325] [Reference Citation Analysis]
23 Zhai B, Ren HY, Li WD, Reddy S, Zhang SJ, Sun XY. Castleman disease presenting with jaundice: A case report and review of literature. World J Clin Cases 2019; 7(3): 373-381 [PMID: 30746379 DOI: 10.12998/wjcc.v7.i3.373] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Li ZY, Kim S, Huang S, Mian R. Multicentric Castleman disease with TAFRO syndrome and Sjögren's. Clin Case Rep 2019;7:2388-92. [PMID: 31893065 DOI: 10.1002/ccr3.2502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
25 Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, Arenas DJ, Ruth JR, Nabel CS, Stone K, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Jordan MB, Cohen AD, Krymskaya V, Rubenstein A, Betts MR, Kambayashi T, van Rhee F, Uldrick TS. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest 2019;129:4451-63. [PMID: 31408438 DOI: 10.1172/JCI126091] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
26 Yue B, Huang J, Jing L, Yu H, Wei D, Zhang J, Chen W, Chen J. Bilateral lung transplantation for Castleman disease with end-stage bronchiolitis obliterans. Clin Transplant 2021;:e14496. [PMID: 34590355 DOI: 10.1111/ctr.14496] [Reference Citation Analysis]
27 Sarosiek S, Shah R, Munshi NC. Review of siltuximab in the treatment of multicentric Castleman's disease. Ther Adv Hematol 2016;7:360-6. [PMID: 27904739 DOI: 10.1177/2040620716653745] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
28 Fajgenbaum DC, Ruth JR, Kelleher D, Rubenstein AH. The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research. Lancet Haematol 2016;3:e150-2. [PMID: 27063967 DOI: 10.1016/S2352-3026(16)00007-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 5.2] [Reference Citation Analysis]
29 Fang X, Sun Z, Xu-Monette ZY, Young KH. Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions. Oncologist 2021;26:4-6. [PMID: 33215784 DOI: 10.1002/onco.13605] [Reference Citation Analysis]
30 Sawaya Z, Semaan DB, Nicolas G, Dib A, Tayar C. Unicentric Castleman's Disease: Laparoscopic Approach of a Para-Duodenal Retroperitoneal Mass. Am J Case Rep 2020;21:e918444. [PMID: 32245939 DOI: 10.12659/AJCR.918444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Cervantes CE, Correa R. Castleman Disease: A Rare Condition with Endocrine Manifestations. Cureus 2015;7:e380. [PMID: 26719823 DOI: 10.7759/cureus.380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
32 Masaki Y, Kawabata H, Fujimoto S, Kawano M, Iwaki N, Kotani T, Nakashima A, Kurose N, Takai K, Suzuki R, Aoki S. Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan. J Clin Exp Hematop 2019;59:175-8. [PMID: 31708515 DOI: 10.3960/jslrt.19021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
33 Wu YJ, Su KY. Updates on the diagnosis and management of multicentric Castleman disease. Tzu Chi Med J 2021;33:22-8. [PMID: 33505874 DOI: 10.4103/tcmj.tcmj_15_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Fajgenbaum DC, Kurzrock R. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. Immunotherapy 2016;8:17-26. [PMID: 26634298 DOI: 10.2217/imt.15.95] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
35 Suarez A, Reilly C, Fajgenbaum DC. Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era. Orphanet J Rare Dis 2019;14:173. [PMID: 31296233 DOI: 10.1186/s13023-019-1145-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Chan KL, Lade S, Prince HM, Harrison SJ. Update and new approaches in the treatment of Castleman disease. J Blood Med. 2016;7:145-158. [PMID: 27536166 DOI: 10.2147/jbm.s60514] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 9.8] [Reference Citation Analysis]
37 Liu B, Huang Y, Tang L, Guan J, Zhou X, Zhan H. Inflammatory pseudotumor of Castleman disease and IgG4-related disease masquerading as kidney malignancy. Diagn Pathol 2021;16:74. [PMID: 34376196 DOI: 10.1186/s13000-021-01134-y] [Reference Citation Analysis]
38 Azariadis K, Ioannou M, Zachou K, Dalekos GN. An Immunocompetent HIV-Negative Elderly Patient with Low-Grade Fever, Generalized Lymphadenopathy, Splenomegaly, and Acute Phase Response: Do Not Forget Castleman Disease. Case Rep Infect Dis 2021;2021:6614208. [PMID: 33777463 DOI: 10.1155/2021/6614208] [Reference Citation Analysis]
39 Cheng JL, Cui J, Wang Y, Xu ZZ, Liu F, Liang SB, Tian H. Unicentric Castleman disease presenting as a retroperitoneal peripancreatic mass: A report of two cases and review of literature. World J Gastroenterol 2018; 24(34): 3958-3964 [PMID: 30228787 DOI: 10.3748/wjg.v24.i34.3958] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
40 Pai RL, Japp AS, Gonzalez M, Rasheed RF, Okumura M, Arenas D, Pierson SK, Powers V, Layman AAK, Kao C, Hakonarson H, van Rhee F, Betts MR, Kambayashi T, Fajgenbaum DC. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight 2020;5:135031. [PMID: 32376796 DOI: 10.1172/jci.insight.135031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
41 Imen BI, Zenaidi H, Abdelwahed Y, Sabeur R, Ayoub Z. Management of isolated retroperitoneal Castelman's disease: A case report. Int J Surg Case Rep 2020;70:24-7. [PMID: 32361607 DOI: 10.1016/j.ijscr.2020.03.048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Freeman SC, Baskaran J, Gbadamosi-Akindele M. Human Herpesvirus-8 Negative Multicentric Castleman Disease in a Patient with Human Immunodeficiency Virus Treated with Highly Active Antiretroviral Therapy and Chemotherapy. Cureus 2019;11:e5530. [PMID: 31523587 DOI: 10.7759/cureus.5530] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Pierson SK, Khor JS, Ziglar J, Liu A, Floess K, NaPier E, Gorzewski AM, Tamakloe MA, Powers V, Akhter F, Haljasmaa E, Jayanthan R, Rubenstein A, Repasky M, Elenitoba-Johnson K, Ruth J, Jacobs B, Streetly M, Angenendt L, Patier JL, Ferrero S, Zinzani PL, Terriou L, Casper C, Jaffe E, Hoffmann C, Oksenhendler E, Fosså A, Srkalovic G, Chadburn A, Uldrick TS, Lim M, van Rhee F, Fajgenbaum DC. ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell Rep Med 2020;1:100158. [PMID: 33377129 DOI: 10.1016/j.xcrm.2020.100158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Kadoura L, Hamza A, Jobran AWM, Habes YMN, Agha S, Alyousfi R, Ayoub K. Unicentric Castleman disease in the mesentery with ambiguous symptoms: a rare case report. J Surg Case Rep 2021;2021:rjab367. [PMID: 34457238 DOI: 10.1093/jscr/rjab367] [Reference Citation Analysis]
45 Yu G, Cao F, Gong H, Liu P, Sun G, Zhang W. Embolization of blood-supply artery followed by surgery for treatment of mesorectal Castleman's disease: case report and literature review. Gastroenterol Rep (Oxf) 2019;7:141-5. [PMID: 28057712 DOI: 10.1093/gastro/gow040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Lyapichev KA, You MJ, Vega F, Solis LM, Medeiros LJ. Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging. Virchows Arch 2020;477:437-44. [PMID: 32152665 DOI: 10.1007/s00428-020-02788-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Erdem B, Karakış L, Asıcıoğlu O, Kıyak H, Yılmaz G. Unicentric Castleman disease; the laparoscopic en bloc resection of a hypervascular giant lymph node in the aortacaval zone. J Turk Ger Gynecol Assoc 2021;22:259-61. [PMID: 33631872 DOI: 10.4274/jtgga.galenos.2020.2020.0092] [Reference Citation Analysis]
48 Simpson D. Epidemiology of Castleman Disease. Hematol Oncol Clin North Am. 2018;32:1-10. [PMID: 29157611 DOI: 10.1016/j.hoc.2017.09.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
49 DeCotiis JL, Lukac DM. KSHV and the Role of Notch Receptor Dysregulation in Disease Progression. Pathogens 2017;6:E34. [PMID: 28777778 DOI: 10.3390/pathogens6030034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
50 Hodl I, Bosch P, Dreo B, Stradner MH. Case Report: Extensive Phosphorylation of Interleukin-1 Receptor-Associated Kinase 4 in a Patient With Schnitzler Syndrome. Front Immunol 2020;11:576200. [PMID: 33123160 DOI: 10.3389/fimmu.2020.576200] [Reference Citation Analysis]
51 Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood 2020;135:1353-64. [PMID: 32106302 DOI: 10.1182/blood.2019000931] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 31.0] [Reference Citation Analysis]
52 Jhan JH, Li CC, Wu WJ, Lee HY. Isolated retroperitoneal Castleman's disease: A case report and literature review. Clin Case Rep 2018;6:1543-8. [PMID: 30147901 DOI: 10.1002/ccr3.1654] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
53 Pierson SK, Shenoy S, Oromendia AB, Gorzewski AM, Langan Pai RA, Nabel CS, Ruth JR, Parente SAT, Arenas DJ, Guilfoyle M, Reddy M, Weinblatt M, Shadick N, Bower M, Pria AD, Masaki Y, Katz L, Mezey J, Beineke P, Lee D, Tendler C, Kambayashi T, Fosså A, van Rhee F, Fajgenbaum DC. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv 2021;5:3445-56. [PMID: 34438448 DOI: 10.1182/bloodadvances.2020004016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Lomas OC, Streetly M, Pratt G, Cavet J, Royston D, Schey S, Ramasamy K; British Society for Haematology (BSH) Committee. The management of Castleman disease. Br J Haematol 2021. [PMID: 34340261 DOI: 10.1111/bjh.17688] [Reference Citation Analysis]
55 Bhogal RH, Wotherspoon A, Khan AK. Mesenteric Castleman's disease mimicking neuroendocrine tumour. Int J Surg Case Rep 2019;63:56-8. [PMID: 31563665 DOI: 10.1016/j.ijscr.2019.09.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Sopfe J, Endres A, Campbell K, Hayes K, Trout AT, Liang X, Lorsbach R, O'Brien MM, Cost CR. Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study. Pediatr Blood Cancer 2019;66:e27613. [PMID: 30680887 DOI: 10.1002/pbc.27613] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
57 Pierson SK, Stonestrom AJ, Shilling D, Ruth J, Nabel CS, Singh A, Ren Y, Stone K, Li H, van Rhee F, Fajgenbaum DC. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. Am J Hematol 2018;93:902-12. [PMID: 29675946 DOI: 10.1002/ajh.25123] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
58 Wong RS. Unicentric Castleman Disease. Hematology/Oncology Clinics of North America 2018;32:65-73. [DOI: 10.1016/j.hoc.2017.09.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
59 Srkalovic G, Marijanovic I, Srkalovic MB, Fajgenbaum DC. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. Bosn J Basic Med Sci 2017;17:81-4. [PMID: 28135567 DOI: 10.17305/bjbms.2017.1930] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
60 Toscano M, Cristina S, Cipriano P, Alves AR. Misdiagnosing multicentric Castleman's disease in an HIV-positive patient. Rev Assoc Med Bras (1992) 2020;66:401-4. [PMID: 32578769 DOI: 10.1590/1806-9282.66.4.401] [Reference Citation Analysis]
61 Zhou YX, Ji Y, Wu S. A CARE-compliant article: Unicentric Castleman disease presenting as a retroperitoneal mass of the upper edge of the pancreas: A case report. Medicine (Baltimore) 2020;99:e19515. [PMID: 32176100 DOI: 10.1097/MD.0000000000019515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Koa B, Borja AJ, Aly M, Padmanabhan S, Tran J, Zhang V, Rojulpote C, Pierson SK, Tamakloe MA, Khor JS, Werner TJ, Fajgenbaum DC, Alavi A, Revheim ME. Emerging role of 18F-FDG PET/CT in Castleman disease: a review. Insights Imaging 2021;12:35. [PMID: 33709329 DOI: 10.1186/s13244-021-00963-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Wu D, Lim MS, Jaffe ES. Pathology of Castleman Disease. Hematol Oncol Clin North Am. 2018;32:37-52. [PMID: 29157618 DOI: 10.1016/j.hoc.2017.09.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
64 Ryu WC, Park MH, Kim H, Koh IC, Kim KN. Rare Location of Castleman's Disease in the Temporal Region: A Case Report Involving a Young Korean Woman and Review of the Literature. Arch Craniofac Surg 2017;18:122-7. [PMID: 28913319 DOI: 10.7181/acfs.2017.18.2.122] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Koff JL, Lonial S. Emerging treatments in Castleman disease - a critical appraisal of siltuximab. Biologics 2016;10:9-15. [PMID: 26869762 DOI: 10.2147/BTT.S60523] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
66 Zhang XX, Jiang L, Wang CY, Gu YY, Li LG, Xia TT, Huang Y, Huang PK, Zhang QL. [Clinical analysis of 30 cases of Castleman disease with different types of thoracic involvement]. Zhonghua Xue Ye Xue Za Zhi 2020;41:149-56. [PMID: 32135633 DOI: 10.3760/cma.j.issn.0253-2727.2020.02.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]